Huge Biopharma Australia

Huge Biopharma Australia is a clinical-stage biotechnology company and a subsidiary of Quantum BioPharma (formerly FSD Pharma). The company is primarily focused on the development of Lucid-MS (Lucid-21-302), a first-in-class, non-covalent small molecule inhibitor of protein-arginine deiminase 2 (PAD2). Lucid-MS is designed as a neuroprotective agent for the treatment of multiple sclerosis (MS), aiming to prevent demyelination and promote myelin repair by reducing myelin citrullination. The company has successfully completed Phase 1 clinical trials in healthy volunteers and received FDA clearance for an Investigational New Drug (IND) application to initiate Phase 2 trials in patients with progressive MS. Huge Biopharma Australia leverages Australia's clinical trial infrastructure and R&D tax incentives to advance its neurodegenerative disease pipeline.